eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
7/2008
vol. 12
 
Share:
Share:
more
 
 
abstract:

Cardiovascular events as the effect of targeted therapy

Sebastian Szmit, Grzegorz Opolski, Cezary Szczylik

Współczesna Onkologia (2008) vol. 12; 7 (318–323)
Online publish date: 2008/11/03
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The introduction of targeted therapies has been a breakthrough in present day oncology. These medicaments have proved their high clinical effectiveness. By working in specific mechanisms and on exactly determined metabolic points, these medicines should have an insignificant percentage of complications. There is a paradox, that they block the cell\'s metabolism, which is very important for cardiomyocytes. The small molecule tyrosine kinase inhibitors, while blocking the pathways of neoangiogenesis in the neoplasm, also raise the risk of cardiotoxicity. They also contribute to the occurrence of myocardial dysfunction and hypertension. These medicaments cause acute coronary syndromes and thromboembolic events. Anti-HER2 therapy is also cardiotoxic. It blocks the receptor which normally protects the heart from impairment factors (ischaemia, toxins, adrenergic stimu-lation). Cardiovascular events related to targeted therapy are very often asymptomatic, without the indicators of myocardial necrosis. This cardiotoxicity is often dependent on usage of other cytostatics (mainly anthracyclines). The response to typical cardiological treatment is very good, and healing is achieved very quickly. The oncological benefit is significantly higher than the potential cardiovascular risk.
keywords:

targeted therapies, cardio-vascular events, heart failure, hypertension, thromboembolic compli-cations, small molecule tyrosine kinase inhibitors, anti-HER2 therapy

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe